[A phase II study of carboplatin in lung cancer. The Carboplatin Cooperative Study Group].
A phase II study of carboplatin in ready-to-use solution (RTU) was conducted in patients with primary lung cancer at 9 institutes throughout Japan. Out of 44 patients entered in this trial, 38 were judged eligible by the extramural review committee. The overall response rate was 18.4% (7/38). The response rate for small cell lung carcinoma was 33.3% (6/18), against 5.0% (1/20) for non-small cell lung carcinoma. As for hematological toxicities, thrombocytopenia (less than 7 x 10(4)/mm3) and leukopenia (less than 3,000/mm3) were observed in 55.3% of cases, respectively. Nausea/vomiting was observed at an incidence of 60.5%. The clinical usefulness of carboplatin in RTU form was found to be comparable with that of carboplatin in lyophilized powder.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D016190:Carboplatin; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D016190:Carboplatin